Table 3.
Parameter | Favourable | Unfavourable |
---|---|---|
Age (years) | 18–35 | >35 |
WBC count | <30 × 109/L | >30 × 109/L (B-cell) >100 × 109/L (T-cell) |
Immunophenotype | Thymic | Pro-T, Mature T Pro-B CD20 expression |
Cytogenetic/molecular data | del(9p) High hyperdiploidy |
t(9;22)/BCR-ABL
t(4;11)/MLL-AF4 Low hypodiploidy Complex karyotype High BAALC expression Aberrations of IKZF1 gene |
Time to CR | Early | Late (>3-4 weeks) |
MRD after induction therapy | Negative (<10−4) | Positive (>10−4) |
WBC: white blood count; CR: complete remission; MRD: minimal residual disease; BAALC: brain and acute leukemia cytoplasmic gene; IKZF1: IKAROS family zinc finger 1 gene.